Skip to content

A clinical study to find the efficacy of Probiotic with Col-Red compared with Col-Red alone on reducing cholesterol in patients with hypercholesterolemia.

A double blinded, randomized, comparative clinical trial to determine the efficacy of Probiotic with Col-Red compared with Col-Red alone on reducing cholesterol in hypercholesterolemia patients. - ColRed+ Probiotic Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/06/002722
Enrollment
30
Registered
2012-06-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I70-I79- Diseases of arteries, arterioles and capillaries

Interventions

Intervention1: ColRed+Probiotic: 15 gms of product twice a day in luke warm water or milk for 2 months Intervention2: ColRed+Probiotic: 30 gms once a day in luke warm water or milk for 2 months Cont

Sponsors

British Biologicals
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • A total of 30 Subjects aged between 18-65 years with known but untreated moderate hypercholesterolemia. • Subjects diagnosed with total cholesterol equal to or above 200 mg/dl and who have LDL-cholesterol levels equal to or above 130 mg/dl • Subjects who give their consent to participate after being informed of the study objectives

Exclusion criteria

Exclusion criteria: • Severe disease necessitating pharmacological intervention • Hepatic disease, gastrointestinal complaints and gastrointestinal ulcers. • Thyroid dysfunction or any kidney disease; • Personal history of cardiovascular illness • Uncontrolled diabetes and uncontrolled hypertension in terms of the WHO criteria (140/90 mmHg) • Known food allergy. • Significant chronic organic or psychiatric disease • Not obtaining informed consent • Pregnant or lactating subjects.

Design outcomes

Primary

MeasureTime frame
â?? The difference between treatment groups in the percent change from baseline to the end of treatment in LDL-Cholesterol Timepoint: At week 2, week 4 and and week 8(study end).

Secondary

MeasureTime frame
â?? Change in other lipid levels (total cholesterol, HDL-cholesterol and triglyceride) â?? Incidence of adverse events â?? Quality of life assessment of the subjects â?? Feedback with regard to product taste and consumption habits Timepoint: At week 2, week 4 and and week 8(study end).

Countries

India

Contacts

Public ContactDr Manjunath

ICBio Clinical Research Pvt. Ltd.

vikram.baburao@icbiocro.com919900111993

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026